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a b s t r a c t
Patients with psoriasis and psoriatic arthritis respond to anti-TNF therapy, but not all pa-
tients maintain effective response, and some do not respond. In this article, we demon-
strate the role of a new pathogenetic pathway to some extent TNF-independent in these 
patients. Anti-IL12-23 is a new and alternate mode of therapy for patients with recalcitrant 
response to anti-TNF.
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Quando anti-TNF não obtém sucesso, anti-IL-12-23 é opção alternativa 
na psoríase e na artrite psoriásica
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r e s u m o
Pacientes com psoríase e artrite psoriásica respondem à terapia anti-TNF, mas nem todos 
os pacientes mantêm uma resposta efetiva e alguns não respondem. Nesse artigo, demons-
tramos o papel de uma nova via patogenética que, até certo ponto, independe de TNF nes-
ses pacientes. Anti-IL-12-23 é um modo terapêutico novo e alternativo para pacientes com 
resposta recalcitrante à medicação com anti-TNF.
© 2014 Sociedade Brasileira de Reumatologia. Publicado por Elsevier Editora Ltda. 
Todos os direitos reservados.
Introduction
Tumor necrosis factor alpha (TNF-α) is a proinflammatory 
cytokine involved in inflammation of the skin and synovi-
um, making it a logical target for the treatment of psoriasis 
(Ps) and psoriatic arthritis (Psa). It has been demonstrated 
that this cytokine plays a fundamental role in the pathogen-
esis of both Ps and Psa through several pathogenetic mech-
anisms, including the expression of adhesion molecules to 
the surface of endothelial cells, keratinocytes, and dendritic 
cells promoting leukocyte migration.1 In the joints, it trig-
gers the production of a variety of cytokines, which in turn 
increase the inflammatory cascade. In the skin, TNF-alpha 
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also leads to a decrease in the apoptosis of keratinocytes, 
thus contributing to a hyperproliferative epidermis. Anti-
TNF-alpha has the potential to provide symptomatic relief 
and help prevent disease progression in Ps and Psa by de-
creasing joint and skin inflammation.2 
Guidelines derived from evidence based clinical trials and 
from clinical practice has established the clinical usefulness 
of all the three anti-TNF agents for the treatment of axial 
and peripheral P and Psa. These agents selectively block the 
role of TNF-alpha and proved to be effective in clinical trials 
and also in clinical practice.3 All the three agents – inflix-
imab, etanercept, and adalimumab – have shown marked 
improvements in disease activity in the PASI-75 of the skin 
and in disease activity indexes ACR20, ACR50, ACR70 when 
compared to patients treated with placebo. However, in our 
and others’ experience, not all patients respond to these 
agents, and in some of them, the initial response is lost 
after variable periods of time.4,5 Although switching to an-
other anti-TNF can boost a secondary response, this may 
also be variable, and, in some patients, no response at all 
can be observed. Currently, two new anti-TNFs are being 
evaluated for the treatment of Psa a humanized form of inf-
liximab by subcutaneous route, golimumab and a pegylated 
form of anti-TNF, certolizumab pegol. Phase-2 preliminary 
studies indicate efficacy similar to the conventional anti-
TNFs.6,7 Surprise as it may be, a few patients develop Ps after 
the treatment with anti-TNFs, and several explanations are 
being developed for this enigmatic observation. One of the 
most attractive is the switch to another inflammatory path-
way after prolonged blockade of TNF.8-10 
Ustekinumab is an immunoglobulin, a human monoclo-
nal antibody that binds with great affinity to the shared p40 
subunit of human interleukin 12 and 23.11,12 Increased pro-
duction of IL-23 (but not of IL-12 mRNA) production can be 
observed in the skin of Ps patients. IL-23 is essential for the 
survival and proliferation of Th17 cells. Previous published 
data have shown CD4 and CD8 cells in Ps lesions, and Ps 
is considered a Th1 disease. However, it has been demon-
strated that the CD4 cells secrete excessive amounts of IL17; 
they are Th17 cells, therefore, and one scenario consists in 
considering Ps as a Th1/Th17-mixed disease.13 
Two clinical studies known as PHOENIX 1 and 2 evaluated 
patients with moderate to severe Ps. PHOENIX 1 studied 66 
patients randomized to receive 45 mg or 90 mg at the weeks 
zero, four, and every 12 weeks. In PHOENIX 2, a similar study 
was performed, but in this time with adjustable doses in 
case of partial responses, totaling 70% of the patients in 
both studies against 3% in the group treated with placebo. 
After 52 weeks, besides a good index of response, no seri-
ous adverse events happened, except minor symptoms at 
upper respiratory tract (apparently common with the use 
of any immunobiological agents), neither anaphylaxis nor 
presence of tuberculosis, being these symptoms still associ-
ated with a very convenient way of administration subcu-
taneously every two to three months. When compared with 
etanercept, it was demonstrated that the response observed 
with ustekinumab was superior in efficacy and side effects 
(Figs. 1, 2, and 3).14-17 Studies with ustekinumab in Psa are 
underway. The superiority of this agent has been demon-
strated versus placebo in controlled trials, reducing signs 
and symptoms in the joints and also in the skin. Phase-3 
results are still pending.18,19 Briakinumab (ABT-974) is an-
other fully human monoclonal antibody against the p40 
subunit of IL12-23, that is currently under evaluation for 
Ps.20 Preliminary results are similar to those observed with 
ustekinumab. Finally, as the activation of IL-23 depends on 
Th17,future biological agents for Ps and Psa might be di-
rected at Th17 and their secreted product IL-17, a pathway 
still not taken in Psoriasis.21 In summary, the current status 
on the therapy of Ps and Psa should now include new medi-
cations despite the fact that after TNF failure, we still lack 
proper guidelines.22,23 
Fig. 1 – Phoenix 1 & 2: study design.
Fig. 2 – Ustekinumab pasi 75 responses at week 12 (after 
doses at weeks 0, 4).
Fig. 3 – Significant efficacy after two injections.
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Conclusions 
It is conceivable that we are not ready to replace anti-TNF as 
an alternative for the treatment of Ps, but it is a possibility, in 
case of Psa, until the ongoing phase-3 studies are available, it 
may also become a possibility in reducing articular signs and 
symptoms. So, what is the alternative if anti-TNF fails in pa-
tients suffering from Ps and Psa? Our understanding is that un-
til comparative studies be performed, inhibition of new patho-
genetic pathways should be considered and evaluated at the 
individual level; moreover, blocking IL12-23 is an alternative 
pathway initially indicated for the skin, although it also seems 
to be helpful in alleviating symptoms of arthritis.24,25 
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